Share Twitter LinkedIn Facebook Email Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.
Edetek’s CONFORM Platform: Streamlining Clinical Data Management in Oncology Trials General 3 Mins Read
High-Dose Chemotherapy for Recurrent Germ Cell Tumors: ASCO 2024 Study Results – Hedyeh Ebrahimi, MD – City of Hope ASCO Annual Meeting 2 Mins Read
